TRAF7 and neoplasm: Furthermore, the combination of TRAF7 inhibition with the second-line drug lomustine, as suggested by the National Comprehensive Cancer Network (NCCN) treatment guidelines, exhibited notable anti-tumor effects both in vitro and in patient-derived GSC assays.